Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H33ClFNO4 |
Molecular Weight | 514.028 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](OC[C@H](O)CNC(C)(C)CC1=CC(F)=C(Cl)C=C1)C2=C(C=CC=C2)C3=CC=C(C(O)=O)C(C)=C3
InChI
InChIKey=UNFHDRVFEQPUEL-DENIHFKCSA-N
InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1
Encaleret (JTT-305 or MK-5442) is a potent oral short-acting calcium-sensing receptor (CaSR) antagonist and transiently stimulates endogenous parathyroid hormone (PTH) secretion.
CaSR antagonists stimulate endogenous PTH secretion through CaSR on the surface of parathyroid cells and thereby may be anabolic agents for osteoporosis. Japan Tobacco and Merck were developing encaleret for the treatment of osteoporosis however development has been discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Antagonist for calcium-sensing receptor. JTT-305/MK-5442]. | 2011 Jan |
|
JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. | 2011 Oct 1 |
|
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. | 2012 Jun |
|
A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. | 2013 Aug |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C169946
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
9473
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
100000175069
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
787583-71-5
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
46917559
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
EF8081AQ6G
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1672973
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY | |||
|
XX-158
Created by
admin on Fri Dec 15 19:14:36 GMT 2023 , Edited by admin on Fri Dec 15 19:14:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)